Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00874185
NCT00874185
Completed
Not Applicable

Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.0 sites720 target enrollmentDecember 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsErectile Dysfunction

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Erectile Dysfunction
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Enrollment
720
Primary Endpoint
SEAR
Status
Completed
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Evaluate satisfaction in people treated with IPDE5 inhibitors over time

Detailed Description

12 first patients that are eligible

Registry
clinicaltrials.gov
Start Date
December 2007
End Date
May 2008
Last Updated
5 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •CV risk factors
  • •Male above 18

Exclusion Criteria

  • •Non-informed consent

Outcomes

Primary Outcomes

SEAR

Time Frame: 6 months

EDITS

Time Frame: 6 months

Secondary Outcomes

  • Medication prescribed(6 months)

Similar Trials

Completed
Phase 4
Satisfaction, Confidence and Naturalness in Men With Psychogenic Erectile Dysfunction (ED)Erectile Dysfunction
NCT01153204Federal University of São Paulo30
Completed
Not Applicable
Follow-up Study on Recipients of Treatment at the Jerusalem Center for the Treatment of PsychotraumaHealthy
NCT00463138Herzog Hospital100
Active, not recruiting
Phase 1
Treatment satisfaction and self-reported symptoms in patients under opioid maintenance therapyOpioid maintenance treatment (OMT) is an important factor in the medical care of opioid-dependent patients. Qualified OMT combined with general medical care and psychosocial support is effective in reduction of morbidity and mortality of opioid dependent patients.Therapeutic area: Not possible to specify
EUCTR2015-002440-13-ATMedical University Innsbruck
Completed
Phase 2
Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon AdministrationHuman Immunodeficiency Virus
NCT00333736Canadian Immunodeficiency Research Collaborative337
Completed
Phase 4
Investigation of patient satisfaction and efficacy of Dovobet Gel in psoriasis patients with poor adherencePlaque Psoriasis
JPRN-jRCTs031180049akagawa Hidemi46